Lakefront Biotherapeutics NV (GLPGF) Fair Value & Analysis
Healthcare · US · Market cap $3.2B
Lakefront Biotherapeutics NV
GLPGF · US
Fair value as of: Jul 17, 2026
From 15 valuation models · updated 6 days ago
Fair value updated Jul 17, 2026, revised from $121.63 to $122.50 (+0.7%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $28.08 – $34.00 · fair‑value band $91.87 – $153.12 · the $28.08 price screens below the $122.50 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Lakefront Biotherapeutics NV (GLPGF) currently trades at $28.08, while our model-based Fair Value estimate is $122.50, implying the stock looks roughly 336.3% undervalued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Lakefront Biotherapeutics NV generated revenue of $1.0B at a net margin of 46.8%. It earns a return on equity of 16.3%. The balance sheet holds a net cash position of $80.9M. The stock trades on a trailing P/E of 5.7. Fundamentals as of Jul 17, 2026
Our scenario range runs from $91.87 (bear case) to $153.12 (bull case); at $28.08, the current price sits below that range. The share trades about 17% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at 336%, GLPGF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Lakefront Biotherapeutics NV reported revenue of $1.1B in FY2025 versus $485M in FY2021, a compound +23.1%/yr. Reported net income was $321M in FY2025.
Is GLPGF fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$54.63 | R$46.79 | -14% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$29.46 | R$21.38 | -27% |
| WuXi Biologics (Cayman) Inc 2269 | HK$30.74 | HK$28.99 | -6% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
| Genmab A/S GMAB | kr 1,704 | kr 209.21 | -88% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Lakefront Biotherapeutics NV (GLPGF) undervalued?
What is the fair value of GLPGF?
What is the quality score of GLPGF?
What is the revenue of Lakefront Biotherapeutics NV (GLPGF)?
What is the net profit margin of GLPGF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Lakefront Biotherapeutics NV analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.